Objective: To investigate the role of 188 Re in human sodium iodide symporter (hNIS) theranostic gene-mediated human glioma imaging and therapy in model mice.
Introduction
Glioma remains one of the most common cancers and is a leading cause of cancer-related deaths worldwide. Furthermore, glioma carries a poor prognosis and survival rate. Aside from tumor resection, radiotherapy is the major curative therapy for glioma. However, patients often develop normal brain tissue necrosis following external radiation [1] ; thus, new therapeutic strategies are required. The theranostic strategy [2, 3] using radionuclide-based imaging reporter genes shows great treatment promise for various clinical fields, particularly in the field of cancer gene therapy.
As a theranostic gene, the sodium iodide symporter (NIS) is a plasma membrane glycoprotein, which mediates active iodide uptake in the thyroid and other tissues [4, 5] . One of the most exciting current areas of NIS research is radioiodine treatment of extrathyroidal cancers by the ectopic transfer of the NIS gene into otherwise non-NIS-expressing cancers. Many investigators have successfully obtained ectopic NIS expression by gene transfer techniques in prostate cancer [6] , melanoma [7] , glioma cells [8] and myeloma cells [9] .
Our previous studies [10] [11] [12] [13] suggest that baculovirus mediate human NIS (hNIS) expression leads to 131 I uptake in several types of tumors and presents as a promising target for gene therapy. Although the baculovirus can mediate gene transduction effectively and achieve desirable expression in various tumor cell lines in vitro, there are still some obstacles to overcome concerning the in vivo application of this system in gene therapy. For example, a major concern is the inactivation of baculovirus by the serum complement in baculovirus-based gene therapy in vivo.
In previous studies [14] [15] , extrathyroidal tissues are generally not able to organify iodide after NIS gene transfer. In the contrast, 131 I accumulates and is organified in the thyroid, which exhibits competitive inhibition in extrathyroidal tumor 131 I uptake, preventing the delivery of a radiation dose high enough to affect cell viability; therefore, the therapeutic efficacy of 131 I is limited [16] . The application of alternative radioisotopes that are also transported by hNIS with a shorter physical half-life and a high energy to 131 I may provide a powerful method for enhancing the therapeutic efficacy of hNIS-targeted radionuclide therapy [17, 18] . 188 Re is a b-emitting radionuclide with a short physical half-life (0.71 day) that has been used in a variety of therapeutic applications in humans, including cancer radioimmunotherapy and palliation of skeletal bone pain [19] . Due to its higher relative energy compared to 131 I, administration of 188 Re offers the possibility of higher energy deposition over a shorter time period. Compared to 131 I (E = 0.192 MeV), 188 Re has been proposed as an ideal alternative emitter (E = 0.778 MeV) to 131 I for cancer treatment. Kang et al [20] investigated 188 Re accumulation of a human hepatocellular carcinoma cell line, SK-Hep1, by transfer of human sodium iodide symporter (hNIS) gene and found it has the potential to be used in hepatocellular carcinoma management. To date, no studies have explored whether lentivirus-mediated hNIS gene expression and 188 Re uptake can be used for glioma imaging and therapy. In this study, we investigated the role of 188 Re as a potential alternative radionuclide for hNIS-mediated imaging and treatment of human glioma in model mice.
Materials and Methods
Plasmid construction, lentivirus preparation, and U87 cell transfection with Lenti-CMV-hNIS
The human NIS gene was removed from the pcDNA3.1-hNIS vector (kindly provided by Dr. Sissy Jhiang from Ohio University, OH, USA) by restriction enzyme digestion. All plasmid construction and lentivirus (Lenti-CMV-hNIS) production was performed according to Life Technologies (Carlsbad, CA, USA) manufacturing instructions. Lenti-CMV-0 with no hNIS was prepared as a control. U87 human glioma cell line (American Type Culture Collection, AT CC) were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 5% CO 2 , 37uC, 100 U/ml penicillin and 100 mg/ml streptomycin. To generate cell lines expressing hNIS controlled by the cytomegalovirus (CMV)-enhancer/promoter, the Lenti-CMVhNIS vector was transfected into U87 cells and selected for weeks according to the manufacturer's instructions. Established cells (U87-hNIS) were confirmed through 188 Re uptake experiments. U87-0 cells transfected with Lenti-CMV-0 (hNIS gene negative) were prepared as controls. Cells were maintained in Dulbecco's modified eagle medium (DMEM; Life Technologies) supplemented with fetal bovine serum (10%), and maintained at 37uC in a humidified atmosphere with 5% CO 2 . Cells were seeded in 24-well plates 24 hours before experiments to achieve a density of 10 5 cells/well at the day of study.
In vitro isotope uptake experiments
188 Re was eluted from a 188 W/ 188 Re generator (LaiTai Company, Suzhou, People's Republic of China) using 0.9% saline. hNIS expression in U87-hNIS cells was tested in vitro by 188 Re uptake as Weiss et al. described previously with minor modifications [21] . All activity data were corrected for decay and normalized. U87-hNIS cells were washed with 0.5 mL Hank's balanced salt solution (bHBSS; HBSS supplemented with 10 mM sodium iodide and buffered with Hepes, pH 7.3) once, and incubated for 1, 2, 5, 10, 20, 30, 60, and 120 minutes, respectively, in the presence of 0.5 mL bHBSS containing 3.7 kBq 188 Re. The cells were then washed twice with ice-cold bHBSS and incubated with 1 mL of 100% ice-cold dehydrated alcohol for 20 minutes. The radioactivity (counts per minute [cpm]) in cell lysates was measured using a multi-well gamma-counter (Shanghai Institute of Nuclear Research Rihuan Instrument Company, China). All experiments were performed in triplicate. U87-0 transfected cells were prepared as a control. 
Sodium perchlorate inhibition study
We used a sodium perchlorate inhibition study to test the specificity of 188 Re uptake. U87-hNIS cells were incubated for 30 minutes in 3.7 kBq 188 Re medium supplemented with sodium perchlorate (Sigma-Aldrich, St. Louis, MI, USA) at concentrations of 0, 1 mM, 2 mM, 5 mM, 10 mM, 20 mM, 50 mM, and 100 mM. Then the cells were washed, lysed, and counted as described previously.
Isotope efflux study in vitro
We evaluated 188 Re efflux kinetics in cells expressing hNIS as previously described by Weiss et al [21] . Briefly, U87-hNIS cells were exposed to 3.7 kBq/well 188 Re at 37uC for 20 minutes. Cell medium was then replaced with fresh, nonradioactive bHBSS. The cells were incubated for 2, 4, 6, 8, 10, 12, 14, 16, 18 or 20 min and immediately lysed as described previously. After the incubation period, the cells were extracted with 1 mL of dehydrated alcohol, and the residual activity in the cells were measured.
In vitro assessment of isotope toxicity by clonogenic assay U87-hNIS and U87-0 cells were seeded in 24-well plates 24 hours before the experiment to achieve a density of 10 5 cells/well on the day of study. As shown in Table 1 , cells were divided into six groups: Group 1 included U87-hNIS cells washed with bHBSS and allowed to incubate for 7 hours (5% CO 2 , 37uC) after the addition of 740 kBq 188 Re/mL; Group 2 was processed as Group 1, but without addition of 188 Re; Group 3 included U87-0 cells washed with bHBSS and allowed to incubate for 7 hours after the addition of 740 kBq 188 Re/mL; Group 4 was processed as Group 3, but without addition of 188 Re; Group 5 included nontransfected U87 cells that were washed with bHBSS and allowed to incubate for 7 hours after the addition of 740 kBq 188 Re/mL; Group 6 was processed as Group 5, but without addition of 188 Re. Groups 2, 3, 4, 5 and 6 all served as controls. The six groups of cells were then washed twice with bHBSS, trypsinized, counted, and plated at a density of 200 cells/well in 6-well plates in triplicate. The cells were placed in 5% CO 2 at 37uC for 7 days. After removing the culture medium, each plate was stained with crystal violet solution (0.1%), and colonies including more than 30 cells were counted. Results are expressed as the percentage of surviving cells, ie, the percentage of colonies obtained after treatment with lentivirus and/or 188 Re compared to treatment with bHBSS alone (Group 6).
Biodistribution of 188 Re in xenografted mice
For biodistribution studies, the U87-hNIS tumor xenografted mice were randomly divided into 4 groups with 6 mice per group. Each animal received a 370 kBq intravenous (i.v.) injection of 188 Re to evaluate biodistribution of the tracer in the tumor and major organs. The mice were sacrificed 0.5 h, 2 h, 12 h and 24 h after the radionuclide injection, the main organs and xenografted tumors were removed, weighed, and counted for radioactivity by using a gamma counter. All tissue counts were corrected for background and decay during the time of counting. Results were expressed as a percentage of the injected dose per gram (% ID/g) of tissue. Each value represents the mean and SD of 6 animals. The U87-0 tumor xenografted mice were served as controls and processed as described above.
Tumor imaging and therapy study in a xenograft model
Animal procedures were carried out following the approval of the Ethics Committee and Animal Care Committee of Shanghai Jiaotong University, School of Medicine. Five-week-old female, athymic Balb/c nude mice were used in the following experiments; six mice were used in each group. A xenograft model was generated by subcutaneous injection of U87-hNIS or U87-0 cells (5610 6 cells suspended in 150 mL phosphate buffered saline) into the right axilla of the mice. Approximately 6 weeks after inoculation when the tumor diameter reached 0.8-1.0 cm, the mice were used for imaging and therapeutic studies.
Xenograft models of U87-hNIS and U87-0 cells were established (n = 6 for each group).
188 Re (55.5 MBq) was injected through the caudal vein. Immediately after intravenous injection of 188 Re into the mice, the time dependent accumulation of radioactivity in the mice was monitored 15 minutes, 0.5, 1, 2, 4, 24, and 48 hours after injection using a c-camera (GE Healthcare, Cleveland, OH, USA), equipped with a high-resolution pinhole collimator with a matrix size of 2566256. Elliptical regions of interest (ROI) were placed on the tumor and on the contralateral armpit region, from which tumor-to-nontumor (T/NT) contralateral armpit count ratios of each group were measured and calculated in every time point.
To evaluate the in vivo effects of hNIS-mediated radioiodine therapy, U87-hNIS tumor size of xenograft models were measured before and after the intravenous injection of 18.5 MBq, 55.5 MBq and 111 MBq 188 Re respectively (n = 6 for each group). U87-0 tumor xenograft models were treated with 55.5 MBq 188 Re and served as controls. All mice were followed for a total of 4 weeks. Tumor volume was estimated using the following formula: length6width 2 60.52.
Statistical analysis
Origin 7.5 (OriginLab Corporation, Northampton, MA, USA) and SPSS 16.0 (IBM Corporation, Armonk, NY, USA) were used for all statistical analyses. Numeric data are expressed as means 6 standard deviation (SD). Data comparisons between groups were performed by analysis of variance (ANOVA) test. P values,0.05 were considered statistically significant. 
Results
We successfully developed a lentivirus-derived vector containing the hNIS gene under the control of the CMV promoter and yielded virus (Lenti-CMV-hNIS) stocks. Lenti-CMV-0 was also prepared as control with the same titer. Approximately 3 weeks later, after infection of U87 cells with the recombinant lentiviruses, stable cell lines U87-hNIS and U87-0 were established. In order to investigate the function of hNIS in the recombinant U87-hNIS cell lines, 188 Re uptake experiments were performed.
hNIS-mediated in vitro 188 Re uptake 188 Re uptake in U87-hNIS cells with respect to 188 Re incubation time is shown in Figure 1 ; the initial uptake of 188 Re was dependent on incubation time. 188 Re influx rapidly increased into U87-hNIS cells, with half-maximal uptake observed at about 5 minutes, reaching a maximum after about 30 minutes. 188 Re uptake in U87-hNIS cells was 26-fold higher than in U87-0 cells after incubation with 188 Re for 30 minutes. At that time point, 188 Re accumulation achieved a peak; therefore, 30 minutes represented the U87-hNIS maximal 188 Re uptake and was selected as the incubation time for subsequent experiments. The intracellular radioactivity was calculated to be up to 3.3% of the total radioactivity in cell lysate and media. Assuming that U87-hNIS cells have a mean diameter of 10 mm, we estimated that an up to 328-fold higher concentration of 188 Re was observed in cells compared to media. The radioactivity measured 2 hours after 188 Re incubation was 93.3% of the maximal uptake. There is a plateau, as Zuckier et al. [22] reported in similar studies, which suggest steady-state uptake.
Sodium perchlorate inhibition study
To evaluate whether 188 Re accumulation was specifically induced by the functional activity of the hNIS gene product, 188 Re uptake was determined in U87-hNIS cells in the presence of various concentrations of sodium perchlorate, an established competitive inhibitor. Figure 2 shows the effect of sodium perchlorate on 188 Re uptake in U87-hNIS cells. Uptake of 188 Re showed dose-dependent inhibition in U87-hNIS cells in experiments performed within a range of 1-50 mM NaClO 4 ; 5 mM NaClO 4 decreased 188 Re uptake to 16.8%, while at a concentration of 50 mM, sodium perchlorate inhibited 188 Re accumulation in U87-hNIS cells by 94.6%.
188 Re uptake was blocked and significantly decreased in the presence of sodium perchlorate, indicating that 188 Re is uptaken through functional hNIS in U87-hNIS cells. 
Radionuclide efflux assay
On reaching maximum 188 Re uptake after approximately 30 min, the 188 Re efflux assay was continued for 20 min ( Figure 1 ). As shown in Figure 3 , the amount of remaining 188 Re in U87-hNIS cell lysate was determined as a function of time after replacement of 188 Re containing media with nonradioactive media. The cellular radioactivity was rapidly and continuously released into the media, with 55.7% of the total cellular 188 Re released within 4 minutes, and 95.5% efflux was observed after 20 minutes, indicating that the radiotracer was rarely trapped in U87-hNIS cells. Accordingly, under in vitro conditions limiting re-uptake, a rapid release of 188 Re was observed.
Re toxicity assessed by colony-forming assay
In vitro 188 Re toxicity experiments were performed on U87-hNIS cells to demonstrate whether it was possible to obtain a cell killing effect with 188 Re. After 188 Re treatment, clonogenic assays were performed, the results of which are shown in Figure 4 . The data is expressed as the percentage of surviving cells. In Group 2 and Group 4, U87-hNIS and U87-0 cells treated without 188 Re, the numbers of colonies were 98.3% and 97.7% of blank cells (Group 6), respectively, indicating that transfection with the lentivirus did not affect cell survival. In Group 3 and Group 5, after exposure to 188 Re, 68.7% and 66.3% of the cells survived, respectively. In Group 1, the number of 188 Re treated U87-hNIS colonies that recovered were significantly lower than in the other five groups, with a survival of about 21.3%, demonstrating a selective killing effect of 188 Re in hNIS-expressing cells, which is the end goal of this system.
Biodistribution of 188 Re in xenografted mice
The biodistribution data of 188 Re in U87-hNIS tumor hNIS Induced xenografted models are illustrated in Fig. 5A . The radiotracer exhibited a rapid decrease in radioactivity over time in blood and most organs. The high activity of stomach was evidently attributable to the excretion of 188 Re in the gastric mucosa. The highest tumor uptake of 188 Re (31.1367.09% ID/g) was found 2 h after injection and keeped to 10.7264.09% ID/g 12 h after injection, even 4.2361.07% ID/g 24 h after injection, suggesting that the 188 Re was present in the U87-hNIS tumor up to at least 24 h after injection. While in U87-0 tumor xenografted mice, the tumor showed little 188 Re uptake. The highest tumor uptake of 188 Re (2.4160.97% ID/g) was found 0.5 h after injection and decreased to 0.5760.19% ID/g 12 h after injection. There is rarely 188 Re retention (0.1760.08% ID/g) 24 h after injection, suggesting that little 188 Re was present in the U87-0 tumor.
Tumor imaging and therapy study 188 Re uptake and efflux in vivo was not consistent with the data obtained from the in vitro studies. For instance, U87-hNIS tumors showed efficient 188 Re uptake in vivo, and 188 Re rapidly and significantly accumulated in the right axilla of mice ( Figure 6A , B, C), leading to scintigraphic visualization, whereas the U87-0 control tumors were not visible ( Figure 6D , E, F). As expected, tissues naturally expressed NIS (in the thyroid and stomach, for example) or in organs involved in 188 Re elimination (such as the bladder) were also visualized, but significantly lower relative to tumor uptake. In U87-hNIS tumors, as shown in Figure 7 , the tracer accumulation increased to maximum levels 1-hour after administration (T/NT 11.7563.27), remained steady up to 24 hours (T/NT 11.5862.96), and 188 Re remained in U87-hNIS tumors even 48 hours later (T/NT 4.8361.55). These are consistent with the results of biodistribution studies in U87-hNIS tumor xenografts. Furthermore, little 188 Re is retained in the thyroid gland; the reason for this is that 188 Re cannot be organified by the thyroid gland, which alongside with its shorter half-life, should substantially reduce the risk of post-treatment hypothyroidism.
As showen in Figure 8 , although U87-hNIS tumors treated with 18.5 MBq 188 Re showed no significant shrinkage, the tumor growth was retarded significantly 4 weeks after treatment, whereas the U87-0 tumors treated with 55. ) showed no statistical significance (P.0.05).
Discussion
Most gliomas are resistant to currently available chemotherapy regimens. Besides tumor resection, external radiotherapy is a major curative therapy for glioma. However, patients are often either not responsive to or suffer from side effects from these conventional therapies. Radionuclide-based theranostic strategies have been widely used in the diagnosis and treatment of patients with hyperthyroidism or differentiated thyroid cancer, and the sodium iodide symporter gene is the radionuclide-based reporter gene used in theranostics. Theranostics is a promising approach offering the ideal combination of accurate diagnosis and successful therapy in various clinical fields, which is expected to become a key area of personalized medicine in the near future. In order to attain the ultimate goals of personalized medicine, which is to provide the highest therapeutic effect and to avoid adverse effects for each patient, a tailored therapeutic plan should be developed by obtaining accurate, detailed diagnostic information regarding the patient's unique circumstances. Theranostics are an example of rapid advancement in biotechnologies for use with theranostic reporter genes and theranostic radiochemistry, which has led to the development of the concept of using theranostics with radionuclide-based imaging reporter genes [3] .
NIS-mediated radionuclide therapy has several features that make it an attractive theranostic approach for the imaging and treatment of gliomas. For instance, complex radiolabeling procedures are not required for NIS-mediated radionuclide therapy. The small sizes of NIS radioactive substrates should result in both increased penetration of the blood-brain barrier and better diffusion capacity within the tumor. Radioisotopes have the potential of a bystander effect, in that tumor cells that do not express NIS can still be destroyed by electrons emitted from the surrounding, transduced tumor cells that express NIS and concentrate the isotope [23] .
The traditionally used 131 I after NIS gene transfer demonstrates limited therapeutic efficacy due to rapid iodide efflux. A strategy to enhance the therapeutic efficacy of NIS-targeted radionuclide therapies in tumors with rapid iodide efflux might be the application of more potent isotopes, such as 188 Re, which are also transported by NIS, but in contrast to 131 I offer the possibility of higher energy deposition in the tumor over a shorter period of time due to its shorter physical half-life and higher energy; together, this suggests a superior therapeutic efficacy in medium or large tumors by an enhanced ''crossfire effect''. In this study, we explored an alternative method of hNIS-mediated therapy using 188 Re. As can be seen from our in vivo study results, the degree of uptake and retention is sufficient for delivery of therapeutic doses of radiation to NIS-expressing tumors, considering the average energy of 188 Re (E = 0.778 MeV vs. 0.192 MeV for 131 I, which is 4.05-fold higher than that of 131 I) and its considerably shorter physical half-life (0.71 days vs. 8.02 days for 131 I) [23] . These properties make 188 Re a worthy candidate for investigating its therapeutic efficacy after targeted NIS gene transfer in nonthyroidal cancers.
In our study, we demonstrated that 188 Re uptake was very rapid in U87-hNIS cells; the initial kinetic of 188 Re uptake was similar to what is observed in other virus transfected cells [24, 25] , reaching a maximum concentration after about 30 minutes.
188 Re accumulation was 26-fold higher compared to U87-0 control cells. There is a plateau phase, as is demonstrated in other studies [24, 25] , which represents the steady-state of transport processes when influx and efflux are balanced [21] . Similar to other NIS related studies, relatively low radionuclide retention was a problem in our in vitro study; the amount of 188 Re retained in U87-hNIS cells decreased significantly. However, U87-hNIS cells were efficiently killed by 188 Re, as revealed by clonogenic assays. In our study, the absorbed dose of 188 Re was sufficient for a significant selective killing effect of 78.7% using 188 Re in an in vitro clonogenic assay, while U87-0 cells showed a non-selective killing effect of approximately 31.3%.
In this context, it is also important to mention that the in vitro monolayer system is an artificial system and does not allow the full assessment of the therapeutic efficacy of a radionuclide due to the lack of a three-dimensional structure, which requires further exploration in in vivo xenotransplant models. Dinglia et al. [26] suggested that therapy depends on adequate retention of the isotope in the tumor. In the absence of iodide organification, hNIS Induced isotope trapping is a dynamic process either due to slow efflux or re-uptake of the isotope by cells expressing NIS. With sufficient NIS expression, iodide efflux is a zero-order process and iodide organification is insignificant. In our in vivo imaging study, 188 Re remained in the U87-hNIS tumor even 48 hours after administration. In the following therapy study, there was a significant difference in tumor size between U87-hNIS mice (317667 mm 3 ) and U87-0 mice (8616153 mm 3 ) treated with 55.5 MBq 188 Re for 4 weeks. Higher dose of 188 Re did not increase therapeutic effect. Unlike thyroid cells, U87-hNIS cells are not polarized and therefore should express hNIS over all regions of their plasma membrane. In vivo, U87-hNIS tumors have a three-dimensional structure that places tumor cells in close proximity to each other. This geometry may allow rapid re-uptake of any isotope that leaks from one cell by surrounding cells and serve as a mechanism for isotope trapping by the tumor, which is in part responsible for the observed therapeutic effect of hNIS and 188 Re in xenograft models. Therefore, cell arrangement can influence cytotoxicity. Studies [27] with hNIS cDNA transfected human glioma cells also showed increased cytotoxicity of 131 I if cells were grouped in a three-dimensional spheroid culture compared to a monolayer culture. This was believed to be due to bystander toxicity, which is maximized in a three-dimensional model. As a corollary, to maximize the therapeutic effect of hNIS, high level transduction and expression are required. Thus, aiming for high level expression of hNIS makes sense not only for maximal radioisotope uptake but also to ensure adequate retention if the isotope is to have its desired effect.
In our study, little 188 Re is retained in the thyroid gland, as 188 Re cannot be organified by this organ. Studies have demonstrated a similar biodistribution pattern for 131 I and 188 Re in mice, with the exception of the thyroid gland, in which only 131 I is retained by organification. In fact, the absence of organification of 188 Re by the thyroid gland may also be considered an advantage for therapy of nonthyroidal hNIS-bearing tissues [18] , in that the thyroid will not serve as a sink for radiopharmaceuticals and will sustain less radiation damage, and more 188 Re can be uptaken by U87-hNIS cells due to 188 Re recirculation. Considering that in our current study a stably hNIS transfected cell line was used with maximum hNIS expression levels, which is not directly applicable for clinical use in humans, the efficacy of 188 Re needs to be evaluated further in future studies after systemic in vivo hNIS gene transfer with the typical limited transduction efficiency and a more heterogeneous hNIS expression pattern. Provided that these studies confirm our findings, 188 Re may serve as an attractive alternative to 131 I, particular in tumors with short iodide retention time.
Conclusions
Our study is the first in vivo application of 188 Re as an alternative radionuclide for the treatment of human glioma after lentivirus transfected sodium iodide symporter gene expression. Transfecting the hNIS gene by a lentiviral vector coupled with 188 Re administration appears to be a novel and promising strategy for tumor imaging and therapy. Moreover, our study, based on the function of hNIS as a theranostic gene allowing the noninvasive imaging of hNIS expression by 188 Re scintigraphy, provides detailed characterization of in vivo vector biodistribution and level, localization, and duration of transgene expression. These are essential prerequisites for precise planning and monitoring of clinical gene therapies that aim to individualize the hNIS gene therapy concept.
